Announcements
July 11, 2024

Yale’s Colton Center for Autoimmunity Funds 11 Research Projects in 2024

Published In:

The Colton Center for Autoimmunity at Yale has announced its 2024 class of awardees, selecting eleven faculty-led projects for grant funding to advance research into autoimmune and allergic diseases. The awards — spanning one development grant and ten pilot grants — come with more than financial support: each recipient also receives expert mentorship, access to industry expertise, and guidance on commercialization strategy.

This year’s cohort reflects the breadth and ambition of the center’s research agenda. Projects target a wide range of conditions including systemic lupus erythematosus and lupus nephritis, antiphospholipid syndrome, asthma and allergies, ANCA-associated vasculitis, age-related macular degeneration, and cystic fibrosis. Among the most distinctive projects is an AI-driven effort to simulate human immune responses in silico — a novel computational approach to modeling autoimmunity — alongside work on rationally designed allergy vaccines, bispecific antibodies, inhaled phage therapy, and small molecule strategies for inducing antigen-specific immune tolerance.

The center, established in 2019 through a gift from philanthropists Judith and Stewart Colton and managed by Yale Ventures, was designed specifically to bridge the gap between promising scientific discovery and commercial viability. Many impactful research breakthroughs stall without the proof-of-concept funding needed to attract industry partners — and these grants are designed to carry researchers across that threshold.

Yale’s Colton Center is part of the broader Colton Consortium, which also includes centers at Penn, NYU, and Tel Aviv University, collectively advancing autoimmunity research on a global scale

AnnouncementsAdaptive ImmunityBiological & MechanisticBiomarker DiscoveryCollaboration & InnovationCross-institutional CollaborationData-Driven & QuantitativeDrug RepurposingMachine Learning & AISystems BiologyTherapeutic DevelopmentTranslational & ClinicalAllergic & Atopic DiseasesAntiphospholipid SyndromeOtherSystemic DiseasesSystemic Lupus Erythematosus (SLE)VasculitisYale University

Featured Experts

Sara Baier, MEd

Sara Baier, MEd

Associate Director of External Relations, Colton Consortium for Autoimmunity

Colton Center for Autoimmunity, Perelman School of Medicine, University of Pennsylvania
Jennifer Gillen, MBA

Jennifer Gillen, MBA

Administrative Manager, Judith & Stewart Colton Center for Autoimmunity (NYU)

Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health, New York University
Kenneth Hassinger

Kenneth Hassinger

Director of Finance, Colton Consortium for Autoimmunity

Colton Center for Autoimmunity, Perelman School of Medicine, University of Pennsylvania

Featured Publications

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab

Diabetologia
Galderisi, A; Sims, EK; Evans-Molina, C; Petrelli, A; Cuthbertson, D; Nathan, BM; Ismail, HM; Herold, KC; Moran, A November 2024
Adaptive ImmunityBiological & MechanisticBiomarker DiscoveryClinical TrialsDisease SubtypingEarly Disease DetectionExperimental Platforms & ModelsHuman CohortsTherapeutic DevelopmentTranslational & ClinicalEndocrine DiseasesType 1 DiabetesYale University

Transcription factor Etv3 controls the tolerogenic function of dendritic cells

Science
Adams, NM; Martinez-Krams, D; Esteva, E; Ra, AC; Alexiou, AI; Jin, H; Yun, TJ; Tellaoui, RS; Mudianto, T; Vollmer, E; Novikova, E; Tan, Y; Huntley, W; Krichevsky, O; Dolgalev, I; Izmirly, P; Buyon, JP; Moreira, AL; Lund, AW; Reizis, B February 2026
Adaptive ImmunityAnimal ModelsBioinformaticsBiological & MechanisticCytokine SignalingData-Driven & QuantitativeDisease SubtypingExperimental Platforms & ModelsHuman CohortsImmune ToleranceInnate ImmunityPrecision MedicineTranslational & ClinicalOtherSystemic DiseasesSystemic Lupus Erythematosus (SLE)New York University
From the Consortium

Related News

What a "Silenced" Chromosome Can Tell Us About Autoimmunity
In the Media Research Findings
June 25, 2026

What a "Silenced" Chromosome Can Tell Us About Autoimmunity

Penn Colton Center researcher Montserrat Anguera reveals how B cells maintain X chromosome inactivation, and how its breakdown drives lupus, offering new insight into female-biased autoimmune disease and treatment targets.

Yale Receives $2.5M Gift to Advance Autoimmune Research
In the Media
June 11, 2026

Yale Receives $2.5M Gift to Advance Autoimmune Research

A $2.5 million gift from the Colton Foundation will advance autoimmune research at Yale School of Medicine and strengthen collaboration across the Colton Consortium for Autoimmunity's four member institutions.

Colton Consortium for Autoimmunity Announces $15 Million Investment
Announcements
June 10, 2026

Colton Consortium for Autoimmunity Announces $15 Million Investment

Penn Medicine has opened a new research facility housing the Colton Center for Autoimmunity alongside immune health, vaccinology, and infectious disease teams — designed to accelerate breakthrough science through collaboration.